Last reviewed · How we verify
treosulfan + cytarabine
Treosulfan and cytarabine work together as a chemotherapy combination that damages DNA in cancer cells, with treosulfan acting as an alkylating agent and cytarabine as a nucleoside analog.
Treosulfan and cytarabine work together as a chemotherapy combination that damages DNA in cancer cells, with treosulfan acting as an alkylating agent and cytarabine as a nucleoside analog. Used for Conditioning regimen for hematopoietic stem cell transplantation in acute myeloid leukemia, Conditioning regimen for hematopoietic stem cell transplantation in acute lymphoblastic leukemia.
At a glance
| Generic name | treosulfan + cytarabine |
|---|---|
| Also known as | ovastat + alexan |
| Sponsor | University of Wuerzburg |
| Drug class | Alkylating agent + nucleoside analog combination |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Treosulfan is a bifunctional alkylating agent that cross-links DNA strands, preventing replication and transcription. Cytarabine is a cytidine analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation. Together, they provide complementary mechanisms of cytotoxicity, commonly used in myeloablative conditioning regimens prior to hematopoietic stem cell transplantation.
Approved indications
- Conditioning regimen for hematopoietic stem cell transplantation in acute myeloid leukemia
- Conditioning regimen for hematopoietic stem cell transplantation in acute lymphoblastic leukemia
Common side effects
- Myelosuppression
- Mucositis
- Nausea and vomiting
- Hepatotoxicity
- Nephrotoxicity
- Infection
Key clinical trials
- Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML (PHASE1, PHASE2)
- Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant (PHASE2)
- Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias (PHASE3)
- Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- treosulfan + cytarabine CI brief — competitive landscape report
- treosulfan + cytarabine updates RSS · CI watch RSS
- University of Wuerzburg portfolio CI